New Zealand to use ‘Magic Mushrooms’ to treat depression

New Zealand’s government, in a groundbreaking decision that signals a major shift in mental-health treatment and drug policies, has approved the medical use psilocybin – the psychoactive substance found in the so-called “magic mushroom” – for treating depression resistant to treatment.

David Seymour (associate health minister) announced Tuesday that psilocybin could be prescribed legally for therapeutic use. This is the first such announcement in the country. New Zealand joins a growing trend in other countries, including Australia, Canada, Switzerland and certain U.S. States.

Seymour explained, “We are giving hope to people that have exhausted all conventional treatments.” “We are moving cautiously, but we are still moving.”

Strict Regulation, Singular Approval

Psilocybin will remain an “unapproved medication” under the new framework. However, psychiatrists are now able to apply for a prescription special authorization in accordance with Section 25 of Medicines Act. The first of these authorities was given to Professor Cameron Lacey. A psychiatrist and academic from the University of Otago, Lacey is the first person to receive this authority.

Strict clinical oversight will be required, as well documentation and patient selection. Currently Prof. Lacey, is the only practitioner who has been approved to administer this substance. However, further approvals will be expected in the coming months.

Seymour said, “It is not about opening floodgates.” “It’s about opening a door—for those who need it most.”

A global psychedelic shift

New Zealand follows Australia, which made a similar decision for 2023. In Australia, psychiatrists are allowed to prescribe psilocybin as well as MDMA in certain cases of mental illness. In the UK, Switzerland and the U.S. there are trials underway, backed by growing scientific support.

Recent studies have revealed promising results. Psilocybin reduces depressive symptoms rapidly and sustainably, especially when combined with professional therapy.

Indigenous and Local Trials

New Zealand has also been host to local research, including trials in Christchurch and a pioneering Māori-centered initiative in Tairāwhiti, where psilocybin therapy was conducted in marae-based settings.

These projects have shown us that a culturally grounded and respectful psychedelic treatment is possible, as well as impactful, said a University of Otago research team spokesperson.

The Road Ahead

Experts and officials in the health field caution that while this is a historic change, psychedelic treatment is not a magic bullet. Patients will be subjected to a thorough screening process, and the treatment will take place in clinical settings. Often, there will also be therapeutic support provided before, during and after a psilocybin experience.

Dr. Lacey said, “It is not only about the molecule.” It’s all about the environment, the preparation and the integration.

Despite ongoing discussions around drug liberalisation the public’s sentiment is cautiously optimistic. Advocacy organizations have welcomed the move, hailing it as a compassionate answer to New Zealand’s mental health crisis. Rates of depression and suicidal thoughts remain high.

As Prof. Lacey prepares to take on his first patients, the country watches closely — and perhaps, with a little more hope.